Oligonucleotide Therapeutics Society
Recent Articles2026-08-24T06:57:48+00:00
14April, 2021

Phase III Trial of ASO Therapy for the Treatment of Huntington’s Disease Halted

Recently, people who have been impacted by Huntington’s disease, their families, and the OTS community were disappointed to learn that the GENERATION HD1 Phase III study of Tominersen was halted based on the recommendation of an unblinded Independent Data Monitoring Committee. Although not based on emergent safety concerns, the ...

11February, 2021

Facts about COVID-19 mRNA Vaccines and the Decades of Research That Went into Creating Them

Posted: February 11, 2021 | Updated: October 8, 2021 Despite the global threat of COVID-19, mRNA vaccines, which are highly effective at preventing COVID-19 illness and have passed rigorous safety standards, have been met with skepticism by many people. This suspicion is due in part to misconceptions and misinformation ...

12January, 2021

Oligonucleotides and the OTS Community Provide Excellent Solutions to the COVID-19 Pandemic

Oligonucleotide therapies are relatively new in the field of medicine, but they have allowed us to make astounding progress in the fight against COVID-19. Rather than simply repurposing existing drugs or spending years to develop new drugs and vaccines, oligo therapies are quickly providing solutions to this global health ...

20March, 2020

Coronavirus Highlights Urgent Need for Science-Backed Research

News Release from Mary Ann Liebert, Inc. publishers Coronavirus Highlights Urgent Need for Science-Backed Research As an academic publisher, we publish many important resources relevant to COVID-19 such as Health Security, Viral Immunology, Telemedicine and e-Health, and Vector Borne and Zoonotic Diseases. We are keeping our finger on the ...

Phase III Trial of ASO Therapy for the Treatment of Huntington’s Disease Halted

April 14th, 2021|Categories: Perspectives on Current Science|

Recently, people who have been impacted by Huntington’s disease, their families, and the OTS community were disappointed to learn that the GENERATION HD1 Phase III study of Tominersen was ...

Comments Off on Phase III Trial of ASO Therapy for the Treatment of Huntington’s Disease Halted

siRNA: From a Powerful Research Tool to Potent Therapeutic Modality

March 30th, 2021|Categories: Perspectives on Current Science|

Earlier this year we celebrated the 20th Anniversary of RNA Interference in Mammalian Cells. In this article, we are going to discuss small interfering RNA (siRNA), a key mechanism ...

Comments Off on siRNA: From a Powerful Research Tool to Potent Therapeutic Modality

Facts about COVID-19 mRNA Vaccines and the Decades of Research That Went into Creating Them

February 11th, 2021|Categories: Perspectives on Current Science|

Posted: February 11, 2021 | Updated: October 8, 2021 Despite the global threat of COVID-19, mRNA vaccines, which are highly effective at preventing COVID-19 illness and have passed rigorous ...

Comments Off on Facts about COVID-19 mRNA Vaccines and the Decades of Research That Went into Creating Them

Oligonucleotides and the OTS Community Provide Excellent Solutions to the COVID-19 Pandemic

January 12th, 2021|Categories: Perspectives on Current Science|

Oligonucleotide therapies are relatively new in the field of medicine, but they have allowed us to make astounding progress in the fight against COVID-19. Rather than simply repurposing existing ...

Comments Off on Oligonucleotides and the OTS Community Provide Excellent Solutions to the COVID-19 Pandemic

Coronavirus Highlights Urgent Need for Science-Backed Research

March 20th, 2020|Categories: Covid-19, Perspectives on Current Science|

News Release from Mary Ann Liebert, Inc. publishers Coronavirus Highlights Urgent Need for Science-Backed Research As an academic publisher, we publish many important resources relevant to COVID-19 such as ...

Comments Off on Coronavirus Highlights Urgent Need for Science-Backed Research

Get the latest news!

  • Category

Go to Top